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Abstract
Background—Release from prison is associated with a markedly increased risk of both fatal and
non-fatal drug overdose, yet the risk factors for overdose in recently released prisoners are poorly
understood. The aim of this study was to identify risk and protective factors for non-fatal overdose
(NFOD) among a cohort of illicit drug users in Vancouver, Canada, according to recent
incarceration.
Methods—Prospective cohort of 2515 community-recruited illicit drug users in Vancouver,
Canada, followed from 1996 to 2010. We examined factors associated with NFOD in the past six
months separately among those who did and did not also report incarceration in the last six
months.
Results—One third of participants (n=829, 33.0%) reported at least one recent NFOD. Among
those recently incarcerated, risk factors independently and positively associated with NFOD
included daily use of heroin, benzodiazepines, cocaine or methamphetamine, binge drug use,
public injecting and previous NFOD. Older age, methadone maintenance treatment and HIV
seropositivity were protective against NFOD. A similar set of risk factors was identified among
those who had not been incarcerated recently.
Conclusions—Among this cohort, and irrespective of recent incarceration, NFOD was
associated with a range of modifiable risk factors including more frequent and riskier patterns of
drug use. Not all ex-prisoners are at equal risk of overdose and there remains an urgent need to
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develop and implement evidence-based preventive interventions, targeting those with modifiable
risk factors in this high risk group.
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1. Introduction
Release from prison is associated with a markedly increased risk of fatal drug overdose,
particularly in the weeks immediately following discharge. Evidence from record linkage
studies suggests that the risk of drug-related death is orders of magnitude higher among ex-
prisoners than among their community peers (Binswanger et al., 2007; Farrell & Marsden,
2008; Kariminia et al., 2007; Rosen, Schoenbach, & Wohl, 2008; Stewart, Henderson,
Hobbs, Ridout, & Knuiman, 2004), and between 3 and 8 times higher in the first two weeks
than the subsequent ten weeks (Merrall et al., 2010). Although it is often assumed that the
key driver of overdose risk for ex-prisoners is reduced drug tolerance (Merrall et al., 2010;
Seaman, Brettle, & Gore, 1998; Strang et al., 2003), empirical support for this view remains
weak (Kinner, 2010).
Reducing the incidence of overdose among recently released prisoners requires an
understanding of who is most at risk and why, so that interventions to prevent or effectively
respond to overdose events can be appropriately targeted and tailored (Darke, 2008).
Unfortunately, although record linkage studies have identified that ex-prisoners are at
increased risk of overdose death, limitations of routinely collected data mean that few risk
factors for fatal overdose in this population have been identified (Kinner, 2010). Existing
evidence suggests that those most at risk have served multiple prison sentences, lack post-
release support from a spouse or partner, and have a history of illicit opiate use (Graham,
2003; Hobbs et al., 2006a; Rosen et al., 2008; Seaman et al., 1998; Singleton, Pendry,
Taylor, Farrell, & Marsden, 2003). Findings regarding age and ethnic minority status have
been mixed, with some studies finding that older and ethnic minority ex-prisoners are at
greater risk (Hobbs et al., 2006b; Stewart et al., 2004; Tobin, Hua, Costenbader, & Latkin,
2007), while others have found the converse (Farrell & Marsden, 2005; Graham, 2003).
Perhaps reflecting reduced drug tolerance, one study has identified abstinence from drug use
in prison as a risk factor for drug-related death post-release (Singleton et al., 2003), while
engagement in prison-based methadone maintenance treatment (MMT) appears to be
protective (Dolan et al., 2005; Kinlock, Gordon, Schwartz, Fitzgerald, & O’Grady, 2009).
Nonfatal overdose (NFOD) is estimated to be between 20 and 30 times more common than
fatal overdose (Darke, Mattick, & Degenhardt, 2003), and is associated with significant
morbidity (Warner-Smith, Darke, & Day, 2002). Relatively few studies have explored risk
factors for NFOD (Strang, 2002) and although the causes of fatal and non-fatal overdose are
likely to be similar (Warner-Smith, Darke, Lynskey, & Hall, 2001), very few studies have
examined NFOD among ex-prisoners. Most studies of NFOD have followed cohorts of
injecting drug users (IDU), and a history of recent incarceration consistently emerges as a
key risk factor (Kerr, Fairbairn, et al., 2007; Seal et al., 2001; Yin et al., 2007). Other
identified risk factors include homelessness, a history of multiple arrests and/or
imprisonments, longer prison sentences, detoxification in the past year, riskier patterns of
injecting such as public injecting and binge drug use, and regular or concurrent use of
multiple drugs including heroin, alcohol, benzodiazepines and cocaine (Coffin et al., 2007;
Kerr, Fairbairn, et al., 2007; Seal et al., 2001; Sergeev, Karpets, Sarang, & Tikhonov, 2003;
Yin et al., 2007). Consistent with the findings from record linkage studies, MMT appears to
be protective (Kerr, Fairbairn, et al., 2007), as does older age (Coffin et al., 2007; Kerr,
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Fairbairn, et al., 2007; Seal et al., 2001). Although empirical evidence remains limited, it has
been argued that systemic disease, particularly hepatic disease associated with hepatitis C
infection, may increase the risk of overdose (Warner-Smith et al., 2001).
Given the high incidence of overdose among those recently released from prison, and
limited knowledge of the risk factors for NFOD among this population, the aims of the
present study were to (a) document the incidence of NFOD among a large cohort of illicit
drug users in Vancouver, Canada, separately for those who had and had not experienced
incarceration recently, and (b) in a multivariate model, identify risk and protective factors
for NFOD among this cohort, separately for those who had and had not experienced
incarceration recently.
2. Methods
The Vancouver Injection Drug Users Study (VIDUS) and AIDS Care Cohort to Evaluate
Access to Survival Services (ACCESS) are open prospective cohorts of illicit drug-using
individuals who have been recruited through self-referral and street outreach from
Vancouver’s Downtown Eastside since May 1996. Those recruited into the VIDUS cohort
are HIV-negative and must have injected an illicit drug at least once in the past six months.
Those recruited into the ACCESS cohort are HIV-positive and must have used an illicit drug
other than or in addition to cannabis in the last 30 days. Members of the VIDUS cohort who
seroconvert during follow-up are automatically transferred into the ACCESS cohort.
At baseline and every six months, participants in both cohorts provide venous blood samples
for HIV and hepatitis C (HCV) testing and complete an interviewer-administered
questionnaire covering demographic characteristics, information about drug use and related
harms, HIV risk behavior, contact with the criminal justice system and enrolment in drug
treatment. All participants provide informed, written consent and receive a CA$20 stipend at
each study visit. The study has been approved by the University of British Columbia’s
Research Ethics Board.
The present analyses included all participants who were enrolled into either VIDUS or
ACCESS between May 1996 and May 2010 (N=2515). The primary endpoint was self-
reported NFOD during the previous six months. Because the focus of the study was NFOD
in the community, interviews conducted in prison settings (n=424) were excluded.
Information on the primary drug involved in overdose was collected from 2001 onwards.
Explanatory variables were selected from those identified in the literature and included
demographic characteristics, patterns of drug use, methadone maintenance treatment
(MMT), HIV and HCV serostatus. Demographic characteristics included age, gender,
Aboriginal ancestry, marital status, employment status, living alone and current
homelessness. Drug use variables included daily use of heroin, cocaine, speedballs (cocaine
and heroin in combination), methamphetamine, morphine, benzodiazepines and >4 alcoholic
drinks; binge drug use and public injecting. For those who reported recent incarceration,
additional explanatory variables included drug injection in prison and, as a proxy for
sentence length, incarceration setting (local/provincial/federal). In Canada, incarceration in
local jails typically lasts for days or weeks, sentences in provincial prisons are up to two
years less a day, and all sentences of two years or more are served in federal penitentiaries.
All time-variant variables referred to the last six months unless otherwise specified.
In order to explore whether the risk factors for NFOD differed as a function of recent
incarceration, the sample was divided into those who did and did not report incarceration in
the last six months. Within each sub-group, we first graphed the annual crude incidence rate
of NFOD per 1000 person years, by dividing the number of NFODs reported in each
Kinner et al. Page 3
Addict Behav. Author manuscript; available in PMC 2013 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
calendar year (1996–2010) by the total person years of observation in that year (defined as
the number of observations divided by two), divided by 1000. Next we examined univariate
associations between potential explanatory variables and NFOD using Pearson’s Chi-Square
test and the Wilcoxon Rank Sum test; variables significant at p<0.10 were included in
subsequent multivariate analyses. Because the analysis included repeated measures of
potential explanatory variables for each participant, we used generalized estimating
equations (GEE) for binary outcomes with logit link for the analysis of correlated data, to
identify factors independently associated with NFOD (Liang & Zeger, 1986). Multivariate
model building proceeded according to the protocol outlined by Pan (2001).
3. Results
Between May 1996 and May 2010 2515 participants were recruited into the study,
contributing a total of 21,798 eligible observations across a median of six follow-up visits
(IQR=2–14). Among this cohort 829 (33.0%) participants reported a total of 1587 NFODs.
Among those recently incarcerated who experienced NFOD, 215 (39%) identified the
primary drug involved: 81.4% identified a CNS depressant (typically heroin), while 18.1%
identified only a stimulant (typically cocaine). Among those who experienced NFOD and
had not been incarcerated recently 637 (62%) identified the primary drug involved: 77.2%
identified a CNS depressant and 22.3% identified only a stimulant.
Table 1 provides descriptive statistics for those who did and did not report recent
incarceration at baseline. Factors positively associated with recent incarceration included
younger age; male gender; homelessness; unemployment; prior incarceration; daily use of
heroin, cocaine, speedballs, morphine and benzodiazepines; recent binge drug use and
public injecting; and history of overdose. Factors negatively associated with recent
incarceration at baseline included HIV infection, living alone and MMT.
Fig. 1 shows the crude incidence rate of NFOD per 1000 person years of observation, among
those who did and did not report recent incarceration, by year 1996–2010. Over this 15 year
period those reporting recent incarceration experienced a total of 554 NFODs giving a crude
incidence rate of 262.7 per 1000 person years of observation, compared with 1035 NFODs
and a crude incidence rate of 117.7 per 1000 person years among those who did not report
recent incarceration. Those recently incarcerated were significantly more likely to report
recent NFOD (OR=2.13, 95%CI 1.89–2.40, p<0.001).
Factors associated with NFOD among those who did and did not report recent incarceration
are shown in Table 2. Among those who reported recent incarceration, factors significantly
associated with NFOD in univariate GEE analyses included younger age; homelessness;
daily use of heroin, cocaine, speedballs, methamphetamine and benzodiazepines; binge drug
use and public injecting; drug injection while incarcerated; and previous NFOD. MMT and
HIV infection were protective. Among those who did not report recent incarceration, the
same factors were significant, except that daily alcohol use emerged as an additional risk
factor, and both previous (not recent) incarceration and HCV exposure were significantly
protective.
Table 2 also shows factors independently associated with NFOD in multivariate GEE
analysis, separately for those who did and did not report recent incarceration. Among those
reporting recent incarceration, NFOD was independently associated with daily use of heroin
(AOR=1.29, 95%CI 1.05–1.59), cocaine (AOR=1.49, 95%CI 1.22–1.83), methamphetamine
(AOR=1.98, 95%CI 1.21–3.22) and benzodiazepines (AOR=1.90, 95%CI 1.29–2.80); binge
drug use (AOR=1.67, 95%CI 1.38–2.03) and public injecting (AOR=1.34, 95%CI 1.10–
1.65); and previous NFOD (AOR=3.87, 95%CI 2.97–5.03). Being older (AOR=0.98 per
year, 95%CI 0.97–0.99), HIV positive (AOR=0.77, 95%CI 0.61–0.99) and receiving MMT
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(AOR=0.64, 95%CI 0.48–0.85) were protective. Among those who did not report recent
incarceration a similar pattern emerged, except that homelessness (AOR=1.31, 95%CI 1.04–
1.64) and daily alcohol use (AOR=1.28, 95%CI 1.03–1.60) emerged as additional risk
factors, previous (not recent) incarceration was protective (AOR=0.80, 95%CI 0.66–0.96),
and being HIV positive was not significantly protective (p>0.05).
Given the unexpected protective effect of HIV for those recently incarcerated, we computed
all two-way interactions between HIV and other factors significant in the multivariate
model. The interaction between HIV and age was significant (p=0.02), and in a subsequent
test of interaction effects (see Table 3) HIV emerged as protective for those ≤38 years of age
(AOR=0.65, 95%CI 0.47–0.88), whereas among those who were HIV negative, being aged
>38 years was protective (AOR=0.74, 95%CI 0.58–0.95).
4. Discussion
In the present study we found that among a large cohort of illicit drug users, the incidence of
NFOD was significantly higher among those who had experienced recent incarceration.
However, the risk factors for NFOD were very similar for those who had and had not
experienced recent incarceration, indicating that preventive interventions designed for
community-based illicit drug users may also be appropriate for those recently released from
prison. Given that most of the risk factors identified pertain to behaviors and circumstances
in the community, preventive interventions delivered prior to release should be coupled with
community-based interventions after release (Freudenberg, Daniels, Crum, Perkins, &
Richie, 2005; Kinner, 2010; WHO, 2010).
Although many IDU continue to use and inject drugs in prison (Calzavara et al., 2003;
Dolan et al., 2010; Jürgens, Ball, & Verster, 2009), much of the debate regarding prevention
of overdose in ex-prisoners has focused on reduced drug tolerance (Merrall et al., 2010;
Seaman et al., 1998; Strang et al., 2003). Although we were unable to directly measure drug
tolerance, our finding that drug injection in prison was a risk factor for NFOD seems
inconsistent with the view that reduced drug tolerance is the overriding risk factor. Although
it is highly likely that drug tolerance is one important factor, this study has identified a range
of other, modifiable risk factors for NFOD, which are very similar to those identified for
illicit drug users who have not been incarcerated recently.
The finding that more frequent, riskier patterns of drug injection was a risk factor for NFOD
is not new (Kerr, Fairbairn, et al., 2007), although this study confirms that the same is true
for illicit drug users who have been incarcerated recently. Regardless of recent incarceration,
risk of NFOD was increased for those reporting public injection or binge drug use. Previous
work has shown that accessing a supervised injection facility (SIF) is associated with a
reduction in public drug use and other risky injecting practices (Stoltz et al., 2007), and that
SIFs can reduce overdose morbidity (Kerr, Small, Moore, & Wood, 2007; Kerr, Tyndall,
Lai, Montaner, & Wood, 2006) and mortality (Milloy, Kerr, Tyndall, Montaner, & Wood,
2008). Given the elevated incidence of NFOD among those recently incarcerated in this
study, there is a clear case for routinely linking incarcerated IDU with a SIF, where
available, both via in-reach before release and as part of a broader case management
approach after release from custody.
Also consistent with previous research (Kerr, Fairbairn, et al., 2007; Ochoa et al., 2005), and
regardless of recent incarceration history, risk of NFOD in this study was elevated for those
reporting daily use of heroin, benzodiazepines, cocaine or methamphetamines. We were
unable to determine whether these drugs were used sequentially or in combination, however
our findings demonstrate that a range of drugs – both depressants and stimulants – are
implicated in overdose among those recently incarcerated. In addition to cautioning
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prisoners that their opiate tolerance may be reduced post-release, preventive interventions
should incorporate messages about the risk of overdose associated with stimulant drugs such
as cocaine and methamphetamine.
Previous studies have identified a link between in-prison MMT and reduced overdose
mortality post-release (Dolan et al., 2005; Kinlock et al., 2009), although it remains unclear
whether in-prison MMT confers a direct protective effect through increased opiate tolerance
at the point of release, or an indirect protective effect by increasing the likelihood of
accessing MMT in the community. In this study, regardless of recent incarceration, current
MMT was associated with reduced risk of NFOD, highlighting both the benefits of MMT as
a harm reduction measure and the particular importance of continuity in treatment provision
for IDU returning from custody to the community (Dolan et al., 2005; Kinner, 2006; Larney,
Toson, Burns, & Dolan, 2012; Møller et al., 2010; Palepu et al., 2004; Wang et al., 2008).
Irrespective of recent incarceration, risk of NFOD also decreased with increasing age.
Although inconsistent with the view that age-related systemic dysfunction should increase
the risk of overdose (Warner-Smith et al., 2001), these findings are consistent with those of
other studies (Coffin et al., 2007; Kerr, Fairbairn, et al., 2007) and may indicate that older
illicit drug users are ‘aging out’ of the risky behaviors that increase risk of NFOD. This
interpretation is consistent with evidence that impulse control is a risk factor for NFOD
(Hakansson, Schlyter, & Berglund, 2008) and that impulsivity declines with age (Steinberg
et al., 2008).
Among those recently incarcerated, risk of NFOD was lower for those who were HIV
positive, although this was only true for younger ex-prisoners. One interpretation of this
finding is that among younger ex-prisoners, HIV diagnosis was associated with increased
access to care and treatment, and a corresponding reduction in overdose risk behaviors. By
contrast, given the high prevalence of HIV among the cohort, among older users remaining
uninfected with HIV may have been a marker for lower levels of overdose risk behavior.
Although potentially important, it remains unclear why this marginally significant finding
was observed and future research could further explore these dynamics.
In this study the most powerful predictor of NFOD was past experience of overdose. Among
those who had been incarcerated recently, the risk of NFOD was almost four times greater
for those who had also overdosed in the past. This finding adds to a growing literature
(Coffin et al., 2007; Darke et al., 2007; Stoové, Dietze, & Jolley, 2009) suggesting that
previous overdose experience does not increase the perception of risk for subsequent
overdose (Darke & Ross, 1997), but rather increases risk. In the context of limited resources
for prisoner and ex-prisoner health initiatives (Belenko & Peugh, 2005; Levy, 2005),
identification of those most at risk of overdose may allow for more effective allocation of
limited resources for prevention. In addition to education and case management, this may
include provision of naloxone to those considered at high risk (Ochoa et al., 2005;
Wakeman, Bowman, McKenzie, Jeronimo, & Rich, 2009).
This study has limitations that should be noted. One limitation is use of self-report, however
self-report can be reliable with hard-to-reach populations (Darke, 1998) and is arguably the
most appropriate way to measure NFOD, since many NFODs are not attended by emergency
services or police and are therefore not documented elsewhere (Darke, Ross, & Hall, 1996;
Dietze, Cvetkovski, Rumbold, & Miller, 2000). Further, we have no reason to believe that
NFODs would be differentially reported by those who were and were not recently
incarcerated. Second, the binary nature of the outcome – any NFOD in the last six months –
means that we under-estimated the incidence of NFOD, because we were unable to
determine how many times a participant had overdosed in this time. Again, we have no
reason to suspect that this would selectively impact those who were or were not recently
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incarcerated. Third, due to limited statistical power we were unable to conduct our analyses
separately for depressant and stimulant overdoses. Although the vast majority of NFODs in
both groups were attributed to depressant drugs (usually heroin), the risk factors for
stimulant overdoses may differ, and should be the subject of further investigation. Fourth,
our sample was not randomly selected and therefore our findings may not be generalizable
to all illicit drug users in Vancouver or elsewhere. A final limitation is that among those
recently incarcerated, we were unable to confirm that the NFOD occurred after, rather than
before, incarceration. However, the markedly elevated incidence of NFOD among those
recently incarcerated is consistent with evidence of increased incidence of fatal OD after
release from custody (Binswanger et al., 2007; Farrell & Marsden, 2008; Kariminia et al.,
2007; Merrall et al., 2010; Rosen et al., 2008; Stewart et al., 2004), which suggests that at
least the majority of NFODs among those recently incarcerated occurred after release from
custody.
In summary, among a large, community-recruited sample of illicit drug users this study
identified a range of modifiable risk factors for NFOD, and found that these risk factors
were similar for those who had and had not experienced incarceration recently. However,
the incidence of NFOD was higher among those incarcerated recently, highlighting the
urgent need for implementation of evidence-based preventive measures both before release
and importantly, after return to the community. Further research is required to understand
the causal mechanisms underpinning overdose in ex-prisoners, so that such interventions can
be appropriately targeted and tailored.
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Fig. 1.
Incidence rate of NFOD per 1000 person years, 1996–2009, among those who did and did
not report recent incarceration.
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Table 1
Descriptive statistics for those who did and did not report recent incarceration at baseline.
Recent incarceration No recent incarceration p value
N=686 N=1829
n (%) n (%)
Mean age in years (range) 35.69 (16.56–56.81) 39.46 (13.26–58.28) <0.0001
Female 205 (29.88) 657 (35.92) 0.0045
Aboriginal ancestry 200 (29.15) 540 (29.52) 0.8562
Married 143 (20.85) 390 (21.32) 0.7941
Living alone 349 (50.87) 1013 (55.39) 0.0432
Homeless 147 (21.43) 256 (14.00) <0.0001
Formal employmenta 104 (15.16) 389 (21.27) 0.0006
Daily heroin usea 355 (51.75) 603 (32.97) <0.0001
Daily cocaine usea 276 (40.23) 483 (26.41) <0.0001
Daily speedball usea 134 (19.53) 159 (8.69) <0.0001
Daily methamphetamine usea 16 (2.33) 39 (2.13) 0.7600
Daily morphine usea 24 (3.50) 41 (2.24) 0.0769
Daily benzodiazepine usea 65 (9.48) 104 (5.69) 0.0007
Daily alcohol use >4 drinksa 55 (8.02) 110 (6.01) 0.0707
MMT 95 (13.85) 416 (22.74) <0.0001
Binge drug usea 318 (46.36) 680 (37.18) <0.0001
Public injectinga 224 (32.65) 359 (19.63) <0.0001
Injected while incarcerateda 65 (9.48) – –
Where incarcerated recentlya
 Local jail 432 (62.97) – –
 Provincial prison 236 (34.40) – –
 Federal prison 18 (2.62) – –
HIV seropositive 155 (22.59) 515 (28.16) 0.0049
HCV seropositive 580 (84.55) 1487 (81.30) 0.0580
Previous imprisonment 682 (99.42) 1316 (71.95) <0.0001
Non-fatal overdose
 Last six months 133 (19.39) 217 (11.86) <0.0001
 Ever 397 (57.87) 924 (50.52) 0.0010
a
In the last six months.
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Table 2
Univariate and multivariate analysis of factors associated with non-fatal overdose among individuals who did
and did not report recent incarceration.
Recently incarcerated Not recently incarcerated
OR (95% CI) AOR (95% CI) OR (95% CI) AOR (95% CI)
Age
 Per year older 0.97 (0.96–0.98) 0.98 (0.97–0.99) 0.95 (0.94–0.96) 0.97 (0.96–0.98)
Gender
 Female vs. male 1.14 (0.91–1.44) 1.20 (1.00–1.42)
Aboriginal ancestry
 Yes vs. no 0.89 (0.69–1.13) 0.98 (0.82–1.18)
 Yes vs. no 1.30 (1.04–1.62) 1.76 (1.44–2.15) 1.31 (1.04–1.64)
Formal employmenta
 Yes vs. no 1.11 (0.85–1.44) 1.00 (0.85–1.18)
Marital status
 Married vs. other 1.04 (0.82–1.31) 0.88 (0.74–1.04)
Live alone
 Yes vs. no 1.12 (0.93–1.35) 1.00 (0.87–1.15)
Heroin injectiona
 ≥Daily vs. less 1.80 (1.48–2.18) 1.29 (1.05–1.59) 2.24 (1.94–2.59) 1.33 (1.14–1.57)
Cocaine injectiona
 ≥Daily vs. less 1.91 (1.59–2.29) 1.49 (1.22–1.83) 2.62 (2.26–3.03) 1.72 (1.47–2.03)
Speedball injectiona
 ≥Daily vs. less 1.75 (1.39–2.22) 2.21 (1.78–2.75)
MA usea
 ≥Daily vs. less 1.78 (1.05–3.03) 1.98 (1.21–3.22) 2.14 (1.38–3.32) 1.97 (1.21–3.19)
Morphine usea
 ≥Daily vs. less 1.01 (0.56–1.83) 1.33 (0.88–1.99)
Benzodiazepine usea
 ≥Daily vs. less 1.96 (1.37–2.81) 1.90 (1.29–2.80) 2.44 (1.92–3.11) 2.11 (1.62–2.75)
Alcohol use >4 drinksa
 ≥Daily vs. less 1.26 (0.91–1.75) 1.40 (1.14–1.71) 1.28 (1.03–1.60)
MMT
 Yes vs. no 0.56 (0.42–0.74) 0.64 (0.48–0.85) 0.45 (0.38–0.55) 0.60 (0.50–0.72)
Binge drug usea
 Yes vs. no 2.02 (1.69–2.41) 1.67 (1.38–2.03) 2.68 (2.35–3.05) 2.09 (1.82–2.40)
Public injectinga
 Yes vs. no 1.64 (1.35–2.00) 1.34 (1.10–1.65) 2.38 (2.01–2.82) 1.46 (1.21–1.76)
Where incarcerateda
 Provincial vs. local 0.89 (0.74–1.07) –
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Recently incarcerated Not recently incarcerated
OR (95% CI) AOR (95% CI) OR (95% CI) AOR (95% CI)
 Federal vs. local 0.64 (0.33–1.24) –
Previous incarceration
 Yes vs. no 1.00 (0.65–1.54) 0.73 (0.61–0.88) 0.80 (0.66–0.96)
Inject while incara
 Yes vs. no 1.52 (1.11–2.08) –
Previous NFOD
 Yes vs. no 3.60 (2.77–4.68) 3.87 (2.97–5.03) 3.04 (2.52–3.66) 3.41 (2.83–4.12)
HIV-serostatus
 Positive vs. negative 0.76 (0.59–0.98) 0.77 (0.61–0.99) 0.80 (0.66–0.97)
HCV-serostatus
 Positive vs. negative 1.37 (0.93–2.01) 0.74 (0.57–0.95)
a
In the last six months.
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Table 3
Multivariate analysis of interaction between HIV infection and age, among those recently incarcerated.
HIV serostatus Age (median split) AORa 95% CI p value
Negative ≤38 years 1.00 Ref. Ref.
Negative >38 years 0.74 0.58–0.95 0.0180
Positive ≤38 years 0.65 0.47–0.88 0.0053
Positive >38 years 0.70 0.48–1.02 0.0639
aAdjusted for daily use of heroin, cocaine, methamphetamine and benzodiazepines; MMT; binge drug use; public drug use; previous NFOD.
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